Get started
Author

Kelly DuPree

Observed names: K. DuPree, K. Dupree, Kelly Dupree, Kelly J. DuPree, Kelly J. Dupree
ORCID: 0009-0006-2747-3918
Observed ORCID: 0009-0006-2747-3918
OpenAlex ID: A5038315593
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
2009 · Hua Tian, Christopher A. Callahan, et al. · Proceedings of the National Academy of Sciences · 420
Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells
2011 · Weiwei Chen, Tracy Tang, et al. · Proceedings of the National Academy of Sciences · 125
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
2018 · A. Italiano, J.R. Infante, et al. · Annals of Oncology · 83
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors
2002 · Hong Xiang, Judith A Fox, et al. · Oncogene · 50
RWJ-54428 (MC-02,479), a New Cephalosporin with High Affinity for Penicillin-Binding Proteins, Including PBP 2a, and Stability to Staphylococcal Beta-Lactamases
2003 · Francois Malouin, Johanne Blais, et al. · Antimicrobial Agents and Chemotherapy · 28
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2023 · Alexandra Drakaki, Thomas Powles, et al. · Clinical Cancer Research · 27
181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
2024 · P. Schmid, S. Loi, et al. · ESMO Open · 25
267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
2021 · A. Sonnenblick, S-A. Im, et al. · Annals of Oncology · 11
PDF
Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)
2025 · Shanu Modi, Timothy A. Yap, et al. · Cancer Research · 9
Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease
2024 · Kyung Hae Jung, Seock-Ah Im, et al. · Cancer Research · 8
Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)
2022 · Sara A. Hurvitz, Valentina Boni, et al. · Cancer Research · 3
2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031
2023 · N. Harbeck, C. Duan, et al. · Annals of Oncology · 2
PDF
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
2020 · Gulam Manji, Nathan Bahary, et al. · Journal for ImmunoTherapy of Cancer · 2
P3‐259: Characterization of the pharmacokinetics, pharmacodynamics, and distribution of anti‐abeta antibody MABT5102A
2009 · Deborah Mortensen, Rong Deng, et al. · Alzheimer s & Dementia · 2
Data from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2023 · Alexandra Drakaki, Thomas Powles, et al. · 1
Abstract 483: TIGIT/PVR/NECTIN immune checkpoint axis expression across breast cancer subtypes
2021 · Kelly J. DuPree, Luciana Molinero · Cancer Research · 1
Abstract 5669: Differential prognosis of immune biomarkers in metastatic vs. early triple negative breast cancer (TNBC) settings
2020 · Kelly J. Dupree, Ching-Wei Chang, et al. · Cancer Research · 1
Abstract 944: Development of predictive and pharmacodynamic biomarker strategies for GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine
2015 · Sami Mahrus, Kelly DuPree, et al. · Cancer Research · 1
Supplementary Figure S3 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Table S7 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Figure S2 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Figure S1 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Table S3 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Figure S4 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Supplementary Table S1 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
2025 · Alexandra Drakaki, Thomas Powles, et al.
Works count: 46
Citation count: 799
H-index: 9
I10-index: 8
Year
Topic
Type